Navigation Links
DK Sinopharma, Inc. is Honored as 'A-class Taxpayer' for the Third Time
Date:12/20/2010

XI'AN, China, Dec. 20, 2010 /PRNewswire-Asia-FirstCall/ -- DK Sinopharma, Inc. (OTC Bulletin Board: DKSP) ("DK Sinopharma" or the "Company") was honored at a grand awards ceremony on December 8, 2010 for its designation as an "A-class taxpayer" in Shaanxi Provincial Tax Paying Credit Rating on September 30, 2010.

"We are very pleased to receive this honor again. It is the third time in a row that the Company has been rated as 'A-class taxpayer' for the two-year period from 2010 to 2011, the first time being for the two-year period from 2006 to 2007 and the second time for the two year period from 2008 to 2009, by both Shaanxi State Taxation Bureau and Shaanxi Local Tax Bureau," said Professor Dongke Zhao, the founder and CEO of DK Sinopharma, Inc. "Ever since the Company was founded, we have continued to improve the financial management system, pay taxes in good faith, and enhance awareness of paying taxes in accordance with the law, which not only has increased the credibility and reputation of our Company but also made great contributions to local economic and social development."

"A-class taxpayer" is the recognition from tax authorities of the government to Companies for their contributions to the Shaanxi economy. The Shaanxi Provincial Tax Paying Credit Rating is assessed by both the Shaanxi State Taxation Bureau and Local Tax Bureau every two years and the companies are usually classified into A, B, C, and D levels related to their Credit standing, among which "A-class taxpayer" is the greatest honor. Those companies designated as "A class taxpayer" have scored more than 95 of 100 in the assessment in accordance with the Provincial Tax Paying Credit Rating Standards.

Only about 900 enterprises received the honor as "A-class taxpayer" among hundreds of thousands of enterprises in Shaanxi Province, among which there are only 15 pharmaceutical companies. The honored enterprises will enjoy exemption from tax inspection for two years (2010-2011) along with other preferential policies.

For more information please see the government website: http://www.sn-n-tax.gov.cn/new-qt/new-content.jsp?pagetype=TPP_CONTENT&wbnewsid=34029&tree=0

About DK Sinopharma,Inc. DK Sinopharma, Inc. has its headquarters in Xi'an, Shaanxi Province, China. The Company identifies, discovers, develops, manufactures and distributes both prescription and over-the counter, including both conventional and Traditional Chinese Medicines, pharmaceutical products for the treatment of some of the most common ailments and diseases. Through the Company's operating entity, Yangling Dongke Maidisen Pharmaceutical Co. Ltd., the Company currently manufactures herbal extracts and 38 pharmaceutical products in the form of capsules, tablets, granules, semisolid ointment, powder, ointment, and paste ointment. The Company focuses on providing remedies to a variety of ailments relating to respiratory, digestive, cardio-cerebral vascular, antineoplastic, bone diseases-modifying antirheumatic, gynecological, and refill nutrition systems, among others. Yangling Dongke Maidisen Pharmaceutical Co. Ltd.'s manufacturing facilities are based in the City of Yangling in Shaanxi Province. Revenue was $20,018,100 and Net Income was $5,161,402 for the nine months ended September 30, 2010. Shareholders' Equity was $22,189,576 and Total Assets were $31,795,702 as at September 30, 2010. For more information see our website at http://www.dksinopharma.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the company's ability to raise additional capital to finance the company's activities; the effectiveness, profitability, and the marketability of its products; legal and regulatory risks associated with the share exchange; the future trading of the common stock of the company; the ability of the company to operate as a public company; the period of time for which its current liquidity will enable the company to fund its operations; the company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; the company's ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed in the company's filings with the Securities and Exchange Commission and available on its website at http://www.sec.gov. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the companies and the industry. The company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. DK Sinopharma, Inc.Mr. Dongke Zhao, President and Chief Executive OfficerMs. Yanhong Ren, Chief Financial OfficerMs. Emily Zhang, Vice President of Corporate Communications86-29-8224-7500-8612ir@dksinopharma.com
'/>"/>

SOURCE DK Sinopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
2. Shu-Tung Li, Founder and CEO of Collagen Matrix, Inc. Honored as 2009 New Jersey Executive of the Year and Company Named Sixteenth Fastest Growing Company
3. Sysmex America Honored Second Consecutive Year as a Company That Cares
4. Omnicells OmniLinkRx Honored With KLAS Award for Product Leadership
5. Roches Quinn Honored as 2010 HBA Rising Star
6. Roche Women Honored as 2010 TWIN Awardees
7. Eleme Medicals President and CEO Nancy Briefs Honored with Leadership Award from Women Entrepreneurs in Science and Technology
8. Omnicells Automated Medication Dispensing System Honored With 2010 Best in KLAS Award
9. Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
10. Hanger Orthopedic Group Honored for its Charitable Relief Efforts in Haiti by InterAction
11. meridianEMR, Inc. Honored by Inc. 5000 for Second Year in a Row as One of the Fastest-Growing Private Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... ITL Limited, ( ASX: ITD ), ... für das zum 31. Dezember 2016 endende Halbjahr ... vorlegen zu können. Eine vollständige Präsentation „Ergebnisse von ... Sie hier . Glanzpunkte ... 2015: 1,04 Millionen USD; +104 %) Gewinn je ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, ... the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the ... April 10. Dr. Bell comes to Liberty from the Ohio University Heritage College ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. ... Dyer started as the Chairman of the Management Committee when IFN was originally formed ... the recruitment of investor/owners and development of the business plan. He became the ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... 2017 partnership with The Jensie Gran Fondo of Marin. For the second year ... with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, ...
(Date:2/23/2017)... ... , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce KLS ... longtime supporter of the event. , "We are pleased that KLS Martin is joining ... 2017 ACPA President. "KLS Martin has a long track record of support of the ...
Breaking Medicine News(10 mins):